Roche Delivers Strong Quarter On Ocrevus Launch, Pipeline Promise
Executive Summary
Roche's strong first quarter and promising array of innovative medicines left investors wondering why it didn't also lift its financial guidance for the year.
You may also be interested in...
Roche's Neuroscience Franchise Gets Lift From Huntington's Breakthrough
Roche is aiming to bolster its future neuroscience franchise with another potential breakthrough product in neurology to add to its clinical-stage efforts in Alzheimer's disease, and its success in developing the first therapy for primary progressive multiple sclerosis, Ocrevus.
Roche Lifts Outlook, Spotlights Perjeta To Drive Growth
A “phenomenal” start by Ocrevus and the use of two other newly launched medicines, Tecentriq and Alecensa, drove sales growth at Roche in the first half of 2017 – with the previously cautious company now upgrading its financial outlook for the year and expecting further growth from breast cancer therapy Perjeta.
Laquinimod Prospects Seen Small After RRMS CONCERTO Trial Failure
Teva has no current plans to further pursue laquinimod in relapsing-remitting multiple sclerosis after the investigational asset, developed by Sweden's Active Biotech, failed in the CONCERTO Phase III trial.